Eansor Norman David 4
4 · Marker Therapeutics, Inc. · Filed Nov 19, 2025
Insider Transaction Report
Form 4
EANSOR N DAVID
Director
Transactions
- Award
Stock Option (Right to Buy)
2025-11-17+84,411→ 84,411 totalExercise: $0.95Exp: 2035-11-17→ Common Stock (84,411 underlying) - Award
Stock Option (Right to Buy)
2025-11-17+137,330→ 137,330 totalExercise: $0.95Exp: 2035-11-17→ Common Stock (137,330 underlying)
Footnotes (2)
- [F1]Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025.
- [F2]Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025.